Kinnate Biopharma Inc.

NasdaqGS:KNTE 株式レポート

時価総額:US$125.1m

Kinnate Biopharma マネジメント

マネジメント 基準チェック /24

Kinnate Biopharmaの CEO はNima Farzanで、 Mar2020年に任命され、 の在任期間は 4.08年です。 の年間総報酬は$ 4.54Mで、 13.4%給与と86.6%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の0.005%を直接所有しており、その価値は$ 5.79K 。経営陣と取締役会の平均在任期間はそれぞれ3.9年と4年です。

主要情報

Nima Farzan

最高経営責任者

US$4.5m

報酬総額

CEO給与比率13.4%
CEO在任期間4.1yrs
CEOの所有権0.005%
経営陣の平均在職期間3.9yrs
取締役会の平均在任期間4yrs

経営陣の近況

Recent updates

Is Kinnate Biopharma (NASDAQ:KNTE) In A Good Position To Invest In Growth?

Jun 11
Is Kinnate Biopharma (NASDAQ:KNTE) In A Good Position To Invest In Growth?

We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

Jan 04
We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

FDA grants fast track nod to Kinnate Biopharma's skin cancer inhibitor

Sep 21

Kinnate Biopharma (NASDAQ:KNTE) Is In A Good Position To Deliver On Growth Plans

Sep 15
Kinnate Biopharma (NASDAQ:KNTE) Is In A Good Position To Deliver On Growth Plans

Kinnate Biopharma GAAP EPS of -$0.62 beats by $0.03

Aug 11

We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

May 15
We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

Companies Like Kinnate Biopharma (NASDAQ:KNTE) Are In A Position To Invest In Growth

Jan 24
Companies Like Kinnate Biopharma (NASDAQ:KNTE) Are In A Position To Invest In Growth

We Think Kinnate Biopharma (NASDAQ:KNTE) Can Afford To Drive Business Growth

Oct 09
We Think Kinnate Biopharma (NASDAQ:KNTE) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Situation

Jun 22
Here's Why We're Not Too Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Situation

We're Not Very Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Rate

Mar 03
We're Not Very Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Rate

Kinnate Biopharma earns bulls as IPO quiet period ends

Dec 28

CEO報酬分析

Kinnate Biopharma の収益と比較して、Nima Farzan の報酬はどのように変化したか?
日付総報酬給与会社業績
Dec 31 2023US$5mUS$608k

-US$113m

Sep 30 2023n/an/a

-US$127m

Jun 30 2023n/an/a

-US$127m

Mar 31 2023n/an/a

-US$122m

Dec 31 2022US$4mUS$583k

-US$116m

Sep 30 2022n/an/a

-US$111m

Jun 30 2022n/an/a

-US$105m

Mar 31 2022n/an/a

-US$99m

Dec 31 2021US$8mUS$558k

-US$90m

Sep 30 2021n/an/a

-US$77m

Jun 30 2021n/an/a

-US$63m

Mar 31 2021n/an/a

-US$49m

Dec 31 2020US$5mUS$359k

-US$36m

報酬と市場: Nimaの 総報酬 ($USD 4.54M ) は、 US市場 ($USD 649.63K ) の同規模の企業の平均を上回っています。

報酬と収益: Nimaの報酬は増加しましたが、会社は利益を上げていません。


CEO(最高経営責任者

Nima Farzan (47 yo)

4.1yrs

在職期間

US$4,539,776

報酬

Mr. Nima Farzan, M.B.A., serves as President and Chief Executive Officer at Kinnate Biopharma Inc. and as a Member of Board of Directors since March 2020. Mr. Farzan had been the Chief Executive Officer at...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Nima Farzan
President4.1yrsUS$4.54m0.0046%
$ 5.8k
Mark Meltz
COO, General Counsel4yrsUS$1.70m0.025%
$ 31.7k
Neha Krishnamohan
CFO, Principal Accounting Officer and Executive VP of Corporate Development2.8yrsUS$2.88m0.046%
$ 58.0k
Robert Kania
Senior Vice President of Research3.8yrsデータなしデータなし

3.9yrs

平均在職期間

47yo

平均年齢

経験豊富な経営陣: KNTEの経営陣は 経験豊富 であると考えられます ( 3.9年の平均在職年数)。


取締役

名称ポジション在職期間報酬所有権
Nima Farzan
President4.1yrsUS$4.54m0.0046%
$ 5.8k
Carl Gordon
Independent Director4.3yrsUS$107.78k0%
$ 0
James Tananbaum
Independent Director3.8yrsデータなし0%
$ 0
Dean Mitchell
Independent Chair3.7yrsUS$139.28k0%
$ 0
Laurie Smaldone Alsup
Independent Director3.7yrsUS$99.28k0%
$ 0
Melissa Epperly
Independent Director3.5yrsUS$110.28k0%
$ 0
Keith Flaherty
Member of Scientific Advisory Board & Independent Director4.3yrsUS$103.28k0.14%
$ 175.9k
Luiz Diaz
Member of Scientific Advisory Boardno dataデータなしデータなし
John Iafrate
Member of Scientific Advisory Boardno dataデータなしデータなし
Andrew Lowy
Member of Scientific Advisory Boardno dataデータなしデータなし
Ryan Corcoran
Member of Scientific Advisory Boardno dataデータなしデータなし
Michael Rome
Independent Director4.3yrsデータなし0%
$ 0

4.0yrs

平均在職期間

52yo

平均年齢

経験豊富なボード: KNTEの 取締役会経験豊富 であると考えられます ( 4年の平均在任期間)。